Fade Upon TOF Stimulation Induced by Succinylcholine

• Status: Completed
• Trial end date: 2017-01-04
• Target enrollment: 0
• Participant gender: All

Summary

Muscle relaxants are medications used during surgery to facilitate surgical access. The effect of the muscle relaxant medications is measured by stimulation a motor nerve and measuring the force of the resultant muscle contraction. Based on the mechanism of action, two kinds of muscle relaxants are described. First a nondepolarizing muscle relaxant and the second kind is the depolarizing muscle relaxant. These two kinds of muscle relaxants can be distinguished by rapidly stimulating the nerve 4 times over 2 seconds (Train of four or TOF). The nondepolarizing muscle relaxants produce fade ie successive muscle contractions are less forceful than the preceding ones. Whereas the depolarizing muscle relaxants are generally believed to produce four contractions of equal strength. However, there is some indication that this may not be entirely correct. There is evidence that depolarizing muscle relaxants also may produce fade. The investigators are conducting the following study to determine if indeed depolarizing muscle relaxants produce fade. The investigators would also like to characterize the fade ie differences during onset and offset of the block and the effect of the dose on the degree on the fade.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Toledo Health Science Campus
• Treatments: Succinylcholine

Criteria

Inclusion Criteria:

• ASA PS I or II,

• 18-60 years of age of either sex,

• with a BMI<25Kg/m2

Exclusion Criteria:

• presence of any disease involving the neuromuscular system.

• Presence of any neurologic illness eg . Paraplegia or hemiplegia, spinal cord injuries, stroke, multiple sclerosis.

• No liver or kidney disease.

• Known allergy to succinylcholine.

• Family history of malignant hyperthermia.

• Known pseudocholinesterase deficiency.

• Any skin burns within the last 1 year.

We would also exclude subjects with;

• Central core disease,

• duchenne or Becker muscular dystrophy,

• osteogenesis imperfecta,

• Noonan syndrome,

• arthrogryposis multiplex,

• congenital,

• myotonia,

• neuroleptic malignant syndrome,

• multiminicore disease,

• King Denborough syndrome,

• Native American myopathy,

• hypokalemic periodic paralysis or

• a history of rhabdomyolysis.

We would also exclude any subject with a history of cardiac arrhythmias.